Small molecule antagonists of Tcf4/β-catenin complex inhibit the growth of HCC cells in vitro and in vivo

International Journal of Cancer

Volumn 126, Issue 10, 2010, Pages 2426-2436

  Wei, Wei ^a   Chua, Mei Sze ^a   Grepper, Susan ^b   So, Samuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CellzDirect Life Technologies   (United States)

Author keywords

catenin; Hepatocellular carcinoma; Wnt signaling

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CGP 049090; CYCLIN D1; MYC PROTEIN; PKF 115584; PKF 118310; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TCF 4; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; BIRC5 PROTEIN, HUMAN; CGP049090; DRUG DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; PERYLENE; PKF115 584; PKF115-584; PKF118 310; PKF118-310; PYRIMIDINONE DERIVATIVE; TCF4 PROTEIN, HUMAN; TRIAZINE DERIVATIVE; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG BINDING; DRUG STRUCTURE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; LIVER CELL; LIVER TUMOR; METABOLISM; NUDE MOUSE; ONCOGENE MYC; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; PERYLENE; PYRIMIDINONES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRIAZINES; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951230705     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24810     Document Type: Article

References (41)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80: 827-841.
2. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F, Cavallari A. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003;237:536-543. (Pubitemid 38176435)
3. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomized trial. Lancet 2000;356:802-807. (Pubitemid 34203177)
4. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, et al.A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130: 187-196
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362: 1907-1917.
6. Oie S, Ono M, Fukushima H, Hosoi F, Yano H, Maruyama Y, Kojiro M, Terada T, Hirano K, Kuwano M, Yamada Y. Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells. Mol Cancer Ther 2007;6: 2310-2318. (Pubitemid 47294759)
7. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-1991.
8. Bild AH, Yao G, Chang JT, Wang Q, Potti A. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357.
9. Devereux TR, Stern MC, Flake GP, Yu MC, Zhang ZQ, London SJ, Taylor JA. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol Carcinog 2001;31:68-73.
10. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-770.
11. WongCM, Fan ST, Ng IOL. β-catenin mutation and over expression in hepatocellular carcinoma. Cancer 2001;92:136-145.
12. Thompson MD, Monga SPS. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007;45:1298-1305.
13. Lee HC, Kim M, Wands JR. Wnt/frizzled signaling in hepatocellular carcinoma. Front Biosci 2006;11:1901-1915.
14. Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets 2008;9: 1013-1024.
15. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701. (Pubitemid 39150127)
16. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3:573-588.
17. Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gammacatenin proteins in hepatocellular carcinoma: Relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 2000;31:558-565.
18. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, Yoshimi F, Fukao K. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: Correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8:450-456. (Pubitemid 34193964)
19. Huang H, Fujii H, Sankila A. β-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155:1795-1801.
20. Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009;49:821-831.
21. Sparks AB, Morin PJ, Vogelstein BKinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-1134. (Pubitemid 28183198)
22. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275: 1790-1792. (Pubitemid 27136716)
23. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-1790. (Pubitemid 27136715)
24. You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, Jablons DM. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004;64:5385-5389. (Pubitemid 39006560)
25. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006;25:3866-3884.
26. Lepourcelet M, Chen YN, France DS. Small-molecule antagonists of the oncogenic Tcf/b-catenin protein complex. Cancer Cell 2004;5:91-102. (Pubitemid 38121599)
27. Wakita K, Tetsu O, McCormick F. A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics. Cancer Res 2001;61:854-858. (Pubitemid 32174391)
28. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, et al.Targeting the b-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007;104:7516-7521. (Pubitemid 47185938)
29. De La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1995;95:8847-8851. (Pubitemid 28350577)
30. Liu Y, Chen C, Wu H, Chan D, Yu J, Yang A. Telomerase and c-myc expression in hepatocellular carcinomas. Eur J Surg Oncol 2004;30:384-390. (Pubitemid 38528922)
31. Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H, Watanabe S, Omata M, Kuriyama S. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 2003;37:534-543. (Pubitemid 36258774)
32. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000;31:1080-1085. (Pubitemid 30233232)
33. Thompson MD, Monga SPS. WNT/β-catenin signaling in liver health and disease. Hepatology 2007;45:1298-1305.
34. Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs 2006;11:469-487.
35. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-b-catenin signaling in hepatocellular carcinoma. Cancer Res 2007; 67:10831-10839. (Pubitemid 350145912)
36. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993;7: 812-821. (Pubitemid 23163585)
37. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989;4:715-724.
38. Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson SS. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of cmyc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 1993;53: 1719-1723. (Pubitemid 23127090)
39. Wu Y, Renard C-A, Apiou F, Huerre M, Tiollais P. Recurrent allelic deletions at mouse chromosomes 4 and 14 in. Myc-induced liver tumors. Oncogene 2002;21: 1518-1526.
40. Shachaf CM, Kopelman A, Arvanitis C, Karlsson A, Beer S, Mandl S. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431: 1112-1117. (Pubitemid 39472236)
41. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3: 45-64.